sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has published a Form 8.3 filing, revealing its position in Avadel Pharmaceuticals plc. This disclosure, mandated by the Irish Takeover Panel, shows interests in relevant securities representing 1% or more. Specifically, Vanguard holds 5,865,286 ordinary shares, equating to a 6.02% stake in Avadel. These shares have a nominal value of US$0.01 each.
The filing reports recent transactions, with a purchase of 686 shares at $21.59 each and a sale of 133 shares at the same price. Vanguard indicates no engagement in derivative agreements or other formal arrangements related to Avadel's securities. Additionally, the filing states there are no indemnities, options, or voting agreements impacting these securities. The disclosure reflects activity as of December 26, 2025.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.